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Figure 2. Current condition
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achieve the target condition that “patients will always
receive the intended duration of chemotherapy,” the
following countermeasures were proposed: 1) Conﬁgure a
hard stop in the chemotherapy drug records to add dura-
tion for safe use outside of the standard treatment plan
template; 2) Standardize communication so all providers
are aware of the intended treatment plan; 3) Create reports
in the electronic medical record to standardize the work
involved in the process of prescribing, veriﬁcation and
administering chemotherapy.
Conclusions: The A3method allowed for rapid identiﬁcation
of the root cause and implementation of target workﬂow.
Countermeasures have been identiﬁed and are currently
being implemented. Implementation of the identiﬁed
countermeasures will be assessed to ensure all chemo-
therapy orders have appropriate durations, including
appropriate follow up adjustments to the process as needed.538
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Background: Patients undergoing allogeneic hematopoietic
stem cell transplantation (HSCT) are at risk for infection
from numerous opportunistic infections. Pneumocystis jir-
oveci pneumonia (PJP) is a potentially life-threatening
infection, which can manifest in immunocompromised in-
dividuals. The risk of PJP after allogeneic hematopoietic
stem cell transplantation (HCT) is approximately ﬁve to
15 percent in the absence of prophylaxis. Current prophy-
laxis for PJP can include trimethoprim-sulfamethoxazole
(TMP-SMX), dapsone, atovaquone and inhaled pentam-
adine (PEN), often with varying breakthrough rates. Issueswith nebulized pentamidine treatment may include poor
adherence to the regimen, coordination with medication
administration and reimbursement. The use of intravenous
(IV) PEN for PJP prophylaxis has been associated with
minimal breakthrough rates in pediatric patients. However,
no large studies have hitherto evaluated the efﬁcacy of IV
PEN for PJP prophylaxis in adult allogeneic HSCT patients.
Methods: We performed a single-institution retrospective
review of electronic medical records of patients who un-
derwent allogeneic HSCT between 1 January 2001 and 1
May 2013, and who had received at least one dose of IV PEN.
Data collected included patient demographics, diagnosis,
previous chemotherapy, pre-transplant conditioning
regimen, other medications, microbiology test results, and
clinical outcomes.
Results: One hundred thirteen (113) patients who under-
went 124 allogeneic HSCTs were included in the study. The
median number of PEN doses administered per patient was 3
(range, 1-23). Seventy-four of the patients (65%) received IV
PEN as primary PJP prophylaxis; thirty-nine (35%) had IV PEN
as second-line prophylaxis post-transplant, most switching
from oral TMP-SMX because of intolerance to that medica-
tion. Side effects of IV PEN administrationwere minimal; one
patient had transient shortness of breath after infusion. No
patients who had received IV pentamidine developed PJP
infection. No cases of PJP were observed in the 124 allogeneic
HSCT recipients who received PJP prophylaxis with agents
other than IV PEN.
Conclusion: This retrospective study showed that IV PEN is
effective in prevention of PJP, with no cases of PJP break-
through and minimal side effects during administration.
Intravenous PEN should be considered as an alternative to
PJP prophylaxis with TMP-SMX, and in situations where
other agents may be contraindicated. Our ﬁndings support
prospective studies of IV PEN in adult allogeneic HSCT
recipients.539
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Background: National guidelines recommend antimicro-
bial prophylaxis for allogeneic hematopoietic stem cell
transplant (HCT) patients during the pre-engraftment
period due to increased infection risk. Fluoroquinolones
have demonstrated lower rates of bacteremia and inci-
dence of neutropenic fever, but there is limited evidence
for the use of alternative antibacterials, such as cefpo-
doxime, for patients with an allergy or adverse effect to
ﬂuoroquinolones.
Methods: This is a single-center, retrospective chart re-
view of adult patients who received an allogeneic HCT
from matched related or matched unrelated donors and
received antibacterial prophylaxis with levoﬂoxacin or
cefpodoxime from January 1, 2011 to September 1, 2013.
The primary objective of this study is to compare the rates
of antibiotic prophylaxis failure between levoﬂoxacin and
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jectives include comparing and characterizing number
and type of infections, mortality at day 100 post-trans-
plant, and hospitalizations for infectious causes in the ﬁrst
100 days of transplant. Additionally, the emergence of
resistance with quinolone and cephalosporin resistant
isolates and number of multi-drug resistant (MDR) in-
fections are characterized.
Results: A total of 80 patients were evaluated (40 levo-
ﬂoxacin, 40 cefpodoxime). Both levoﬂoxacin and cefpo-
doxime groups had similar median age, underlying
malignancy, stem cell source and transplant type. In the
levoﬂoxacin group, 70% of patients received myeloablative
conditioning versus 83% in the cefpodoxime group. Median
antimicrobial prophylaxis days were 10 versus 12 days for
levoﬂoxacin and cefpodoxime respectively. For levo-
ﬂoxacin and cefpodoxime groups respectively, neutropenic
fever occurred in 27 patients (68%) vs. 22 patients (55%),
with antibiotic escalation occurring in 93% and 92% of pa-
tients with neutropenic fever. In those patients requiring
antibiotic escalation, 60% and 52% of patients had positive
cultures in levoﬂoxacin versus cefpodoxime groups,
respectively. There were similar incidences of C. difﬁcile
and MDR infections among both levoﬂoxacin and cefpo-
doxime groups. However, higher rates of extended spec-
trum beta-lactamase-producing E. coli infections were
observed in the cefpodoxime group and higher rates of
methicillin-resistant Staphylococcus aureus infections were
noted in the levoﬂoxacin group. Rates of infections, hos-
pitalizations, and mortality in the ﬁrst 100 days were
similar among both groups.
Conclusion: Though this chart reviewwas limited by a small
sample size, similar rates of antibiotic prophylaxis failure
were demonstrated with the levoﬂoxacin and cefpodoxime
groups. Cefpodoxime can be considered as an alternative to
levoﬂoxacin for antibiotic prophylaxis in allogeneic stem cell
transplant patients.540
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Invasive fungal infections remain one of the most serious
complications of hematopoietic stem cell transplantation,
occurring in 10-20% of recipients, with mortality rates
exceeding 50%. The epidemiology of invasive fungal in-
fections has changed in recent decades requiring changes in
drug therapy for both prophylaxis and treatment.
Voriconazole, a triazole antifungal with mold coverage, is
being used more widely due to this changing epidemiology
which has resulted in the need for more frequent therapeutic
drug monitoring to evaluate efﬁcacy and safety.
The Infectious Disease Society of America recommends
therapeutic drug monitoring of voriconazole secondary to
the known wide inter- and intra-patient variability and ge-
netic polymorphisms. It has been previously demonstrated
that voriconazole follows linear pharmacokinetics in pedi-
atric patients at doses less than 7 mg/kg, however current
increased dosing recommendations exceed this dose. In
addition, increased doses may increase the risk of adverse
effects including hepatic enzyme alteration and central
nervous system effects. These clinical practice changes
further advocate for therapeutic drug monitoring.Pediatric dosing recommendations for voriconazole were
recently increased based on the inability to reach thera-
peutic drug concentrations between the recommended
range of 1-6 mCg/mL, particularly in patients less than 2
years of age. Based on these studies and recommendations,
dosing strategies at our institution were updated to 9 mg/
kg twice daily to a maximum dose of 350 mg in patients
less than 12 years of age and 6 mg/kg twice daily to a
maximum dose of 400 mg for 2 doses followed by 4 mg/kg
twice daily to a maximum dose of 200 mg for patients
greater than or equal to 12 years of age. Of the thirteen
voriconazole levels collected, 23% were within goal range,
23% were above goal range, and 54% were below goal
range. None of the patients experienced hepatic enzyme
elevations or central nervous system effects causing
discontinuation of voriconazole. The small number of pa-
tients within goal range supports the inter- and intra-pa-
tient variability previously reported. For this reason, close
evaluation of voriconazole levels and genetic poly-
morphism testing prior to initiation is warranted.541
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Thiotepa-containing conditioning regimens remain standard
of care for certain malignancies in several pediatric hema-
topoetic stem cell transplant centers. Most commonly, thio-
tepa containing regimens are utilized in autologous
preparative regimens for central nervous system tumors;
however, it has also been utilized in regimens for neuro-
blastoma. These two diagnoses are among the most common
diagnoses for autologous stem cell transplantation in our
institution. Currently there is only one manufacturer of
thiotepa, which has resulted in marked price increases over
the past several years. Typical drug cost for thiotepa can
exceed $100,000 for the conditioning regimen of one
adolescent. Thiotepa costs have exceeded $285,000 for 5
patients over the course of the past 24 months at our single
institution.
The rise in thiotepa costs has resulted in a need to further
evaluate alternative conditioning regimens. Pediatric data
exists to support the use of conditioning regimens such as
busulfan/melphalan and carboplatin/etoposide/melphalan
in other pediatric oncologic disease states. There remains a
need for more robust clinical trial data comparing the efﬁ-
cacy and safety between these alternative conditioning reg-
imens to further determine if there is true beneﬁt of a
thiotepa-containing conditioning regimen.
As data remains lacking on the superiority of a certain pre-
parative regimen for pediatric oncologic disease states such
as central nervous system tumors, it is imperative to assess
the potential pharmacoeconomic impact of utilizing non-
thiotepa containing regimens. When comparing condition-
ing regimens, drug cost would be $109,378 for a thiotepa/
cyclophosphamide regimen in a patient with a body surface
area of 2 m2. Comparatively, a conditioning regimen of
cyclophosphamide/etoposide/melphalan would cost $9,825
in a patient with a BSA of 2m2. A thiotepa/cyclophosphamide
regimen roughly costs ten times the cost of cyclophospha-
mide/etoposide/melphalan and three times the cost of a
busulfan/melphalan containing regimen. The opportunity to
